李氏大药厂(00950)：FDA批准《ADASUVE®》的补充新药上市申请

智通财经01-27

智通财经APP讯，李氏大药厂(00950)发布公告，《ADASUVE®》(洛沙平吸入粉剂，一种单剂量、单次使用的药械组合产品)的补充新药上市申请已于2025年12月29日获美国食品药品监督管理局(FDA)批准。根据《美国联邦食品、药物及化妆品法》(U.S. Federal Food, Drug, and Cosmetic Act)第505(b)(2)条，获批补充新药申请授权将《ADASUVE®》的...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2606789993?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-01-27 20:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2606789993","market":"fut","top_or_hot":-1,"title":"李氏大药厂(00950)：FDA批准《ADASUVE®》的补充新药上市申请","media":"智通财经","content":"<div>\n<p>智通财经APP讯，李氏大药厂(00950)发布公告，《ADASUVE®》(洛沙平吸入粉剂，一种单剂量、单次使用的药械组合产品)的补充新药上市申请已于2025年12月29日获美国食品药品监督管理局(FDA)批准。根据《美国联邦食品、药物及化妆品法》(U.S. Federal Food, Drug, and Cosmetic Act)第505(b)(2)条，获批补充新药申请授权将《ADASUVE®》的...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1398137.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>李氏大药厂(00950)：FDA批准《ADASUVE®》的补充新药上市申请</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n李氏大药厂(00950)：FDA批准《ADASUVE®》的补充新药上市申请\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-27 20:06 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1398137.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，李氏大药厂(00950)发布公告，《ADASUVE®》(洛沙平吸入粉剂，一种单剂量、单次使用的药械组合产品)的补充新药上市申请已于2025年12月29日获美国食品药品监督管理局(FDA)批准。根据《美国联邦食品、药物及化妆品法》(U.S. Federal Food, Drug, and Cosmetic Act)第505(b)(2)条，获批补充新药申请授权将《ADASUVE®》的...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1398137.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1398137.html","article_id":"2606789993","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2606789993","pubTimestamp":1769515574,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，李氏大药厂 发布公告，《ADASUVE》的补充新药上市申请已于2025年12月29日获美国食品药品监督管理局批准。取得FDA批准后，位于加州弗里蒙特的生产设施已获授权于美国境内进行《ADASUVE》的商业化生产。NPI取得FDA批准，标志着集团达成关键监管里程碑，亦代表与公司首项美国制药设施收购相关的监管要求已经完成。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1191":"制药","BK1587":"次新股","BK1574":"生物医药B类股","06622":"兆科眼科-B","00950":"李氏大药厂","BK1583":"高瓴概念"},"translate_title":"Lee's Pharmaceuticals (00950): FDA approved \"ADASUVE\" ® \"Supplementary new drug marketing application","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00950":1.5,"06622":1.5},"content_text":"智通财经APP讯，李氏大药厂(00950)发布公告，《ADASUVE®》(洛沙平吸入粉剂，一种单剂量、单次使用的药械组合产品)的补充新药上市申请已于2025年12月29日获美国食品药品监督管理局(FDA)批准。根据《美国联邦食品、药物及化妆品法》(U.S. Federal Food, Drug, and Cosmetic Act)第505(b)(2)条，获批补充新药申请授权将《ADASUVE®》的商业生产设施由加州山景城(Mountain View, California)迁往加州弗里蒙特(Fremont, California)。是项申请由原拥有人于2025年8月29日提交予FDA，其后，公司的全资附属公司Nova Pneuma Incorporated(NPI)于2025年12月收购有关资产。取得FDA批准后，位于加州弗里蒙特的生产设施已获授权于美国境内进行《ADASUVE®》的商业化生产。NPI取得FDA批准，标志着集团达成关键监管里程碑，亦代表与公司首项美国制药设施收购相关的监管要求已经完成。董事会认为，是项批准支持集团策略性地基于《Staccato®》平台扩大其创新药物递送技术组合，此组合具备应用于多种适应症治疗方案的潜力，并与公司的全球扩张策略及持续致力于监管合规与药品品质的承诺相契合。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2606789993","isCrawlerRequest":true}